Rendezvous BioSciences May 11, 2006

1
(No Transcript)
2
Rendez-vous BioSciencesMay 11, 2006
3
Outline

• Universities and start-ups
• Experience at UNB with start-ups
• UNB and Atlantis BioActives

4
UNB Mission

• Powers teaching, research, and service
• Mission includes
• to achieve national and, in selected areas,
  international recognition for its research
  programs
• to serve New Brunswick, the Atlantic Region and
  the Nation through the development of applied
  programs involving the private sector and
  government agencies
• to serve as a source of information and expertise
  to help society understand and deal with the
  major issues and opportunities of our time

5
UNB Technology Transfer
6
AUTM U.S. Licensing Survey 2004
7
UNB RD and Technology Transfer Deals with
Start-ups
2001 Q1 Labs 2002 Atlantis
BioActives 2003 Atlantic
Hydrogen Kebony 2004
Diaphonics 2005 HSM Systems
Green Imaging 2006 Trio
8
Elements

• Market Opportunity
• Leadership
• Team
• Incubation/Development Plan
• Financing

9
Network Security Software

• Stage
• Product - QRadar
• Commercial Partner
• Q1 Labs
• Milestones
• Invention in 2000
• Tech transfer in 2001
• Series A 5M in 2003
• Series B 18.8M in 2003
• Series C 13M in 2004

10
Wood Treatment Technology

• Stage
• Product
• Partner
• Wood Polymer Technologies/Kebony Products (Oslo)
• Milestones
• Invention 1993
• First commercial plant 2003

11
Voice Authentication Software

• Stage
• Beta Testing
• Partner
• Diaphonics
• Milestones
• Project conception in 2003
• Financing and contacts in place in 2004
• Completion of RD in 2006
• Beta test in 2006

12
Carbonsaver production of hydrogen-rich natural
gas

• Stage
• Pilot
• Partner
• Atlantic Hydrogen (Fredericton)
• Milestones
• AIF Financing 2004
• UNB Contract 2004
• SDTC Financing 2005
• Pilot Launch 2006

13
MRI Software for Measurement for Porosity of Oil
in Rock

• Stage
• Beta Testing
• Partners
• Green Imaging Technology (Fredericton), Bruker
  Instruments (Toronto), Chevron (Houston)
• Milestones
• Developed under AIF 2002 to 2004
• NSERC I2I I 2005
• NSRRC I2I II - 2006

14
Hydrogen Storage Material

• Stage
• Proof of Concept
• Partner
• HSM Systems (Fredericton)
• Milestones
• Invention in 2004
• Patent applications filed in 2005
• License in 2005
• Financing from AIF and others in 2006

15
UNB and Atlantis BioActives
16
Atlantis BioActives

• Privately held Canadian corporation, operating in
  Charlottetown since February 2002
• Functions as a vehicle for expansion to BioVectra
  DCL, the biopharmaceutical division of Diagnostic
  Chemicals Limited

17
Vision and Focus

• Atlantis BioActives as the premier provider of
  taxanes from Ground Hemlock to the generic and
  proprietary markets for paclitaxel and 10-DAB
• Focus
• Extraction Purification
• Enriched taxane extracts
• Natural taxane APIs and intermediates from Taxus
  canadensis
• Semi-synthesis
• Taxane APIs and intermediates from 9-DHB

18
(No Transcript)
19
UNB Initial Invention

• 9-dihydro-13-acetylbaccatin III (9DHB) is one of
  the chemicals obtained from Ground Hemlock
• 9DHB is used to produce, 10-deacetylbaccatin III
  (10DAB), a useful intermediate for the
  preparation of paclitaxel and analogues
• The UNB invention is a method to convert 9DHB
  into 10DAB by a simple three-step process

20
UNB Technology Transfer
21
Key Elements

• Market Opportunity
• Leadership
• Team
• Incubation/Development Plan
• Financing

22
BioVectras API Facility

• 33,000 sq. ft. modular plant design, expandable
  to 8 operational production suites.
• Commissioning and validation in accordance with
  ICH/Q7A/FDA Guidelines (January, 2003).
• FDA acceptance and registration number
  (September, 2003).
• Designed/operated to meet cGMP and environmental
  requirements.
• Active pharmaceutical ingredients, advanced
  pharmaceutical intermediates and bioactive
  natural compounds.
• Bioextraction, purification, organic synthesis,
  and fermentation
• FDA PAI approval letters June 2003 June 2005 (2
  DMFs fermentation human injectable)

23
Atlantis BioActives Facilities

• Facilities leased from BioVectra DCL
• Extraction suite
• Chromatography suite
• Reactor suite (commercial)
• Reactor suite (pilot 10,30 and 50 gal.)
• Laboratories
• Tank farm/Warehousing
• Office/Staff areas

24
Equipment
25
BioVectra Affiliation

• cGMP - Quality Control
• Research Development
• Regulatory Compliance

• All enhanced through our affiliation with
  BioVectra

26
Atlantis 9DHB to 10 DAB License
2001 Due Diligence Assignment
Agreement Option Agreement/MTA 2002 US
patent application filed 2003 Cdn
and other applications filed 2004 US patent
issued 2005 License Agreement 1
gram 10 gram 100 gram 100 Kg/annum
27
Taxane RD Initiative

• Focus of Research
• Process improvement for purification to API-grade
  paclitaxel
• Semi-synthesis for conversion of 9-DHB to 10-DAB
• Semi-synthesis of paclitaxel and docetaxel from
  9-DHB
• Resource enhancement

28
Taxane RD Initiative
Active Pharmaceutical Ingredients and Advanced
Intermediates from Eastern Canadian Natural
Resources of Taxanes

• 6.5 million project for Atlantis
• 4 million awarded to Atlantis October 2003 by
  the Government of Canada

• Atlantis BioActives
• BioVectra DCL
• University of New Brunswick

29
Thank you